Should I buy or sell Keros Therapeutics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Keros Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KROS shares. View KROS analyst ratings or view top-rated stocks .

What is Keros Therapeutics' stock price target for 2024?

7 brokers have issued twelve-month price targets for Keros Therapeutics' stock. Their KROS share price targets range from $60.00 to $105.00. On average, they predict the company's share price to reach $86.00 in the next year. This suggests a possible upside of 47.6% from the stock's current price. View analysts price targets for KROS or view top-rated stocks among Wall Street analysts .

How have KROS shares performed in 2024?

Keros Therapeutics' stock was trading at $39.76 at the start of the year. Since then, KROS shares have increased by 46.6% and is now trading at $58.28. View the best growth stocks for 2024 here .

Are investors shorting Keros Therapeutics?

Keros Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 2,100,000 shares, an increase of 9.4% from the March 15th total of 1,920,000 shares. Based on an average daily trading volume, of 413,400 shares, the short-interest ratio is currently 5.1 days. View Keros Therapeutics' Short Interest .

When is Keros Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our KROS earnings forecast .

How were Keros Therapeutics' earnings last quarter?

Keros Therapeutics, Inc. (NASDAQ:KROS) released its earnings results on Friday, March, 1st. The company reported ($1.34) earnings per share for the quarter, topping analysts' consensus estimates of ($1.37) by $0.03. The company had revenue of $0.14 million for the quarter. During the same quarter last year, the business posted ($1.09) earnings per share.

What ETFs hold Keros Therapeutics' stock?

ETFs with the largest weight of Keros Therapeutics (NASDAQ:KROS) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO) , Virtus LifeSci Biotech Clinical Trials ETF (BBC) and BNY Mellon Innovators ETF (BKIV) . Invesco Dorsey Wright Healthcare Momentum ETF (PTH) .

What other stocks do shareholders of Keros Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Keros Therapeutics investors own include AbbVie (ABBV) , Brainstorm Cell Therapeutics (BCLI) , Cloudera (CLDR) , CVS Health (CVS) , Inovio Pharmaceuticals (INO) , Iovance Biotherapeutics (IOVA) , Karyopharm Therapeutics (KPTI) , Neurocrine Biosciences (NBIX) , Novavax (NVAX) and Pfizer (PFE) .

When did Keros Therapeutics IPO?

Keros Therapeutics (KROS) raised $75 million in an IPO on Wednesday, April 8th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, SVB Leerink and Piper Sandler served as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.

Who are Keros Therapeutics' major shareholders?

Keros Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Perpetual Ltd (0.02%). Insiders that own company stock include Christopher Rovaldi, Jennifer Lachey , Julius Knowles , Keith Regnante and Richard K Prins. View institutional ownership trends .

How do I buy shares of Keros Therapeutics?

Shares of KROS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Positive News SentimentPositive News

NASDAQ:KROS

Keros Therapeutics (KROS) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free KROS Stock Alerts

$58.28

-0.67 (-1.14%)

(As of 04/19/2024 ET)

Compare

Today's Range: $56.15
▼
$59.90
50-Day Range: $56.18
▼
$70.48
52-Week Range: $27.02
▼
$73.00

Volume: 348,567 shs
Average Volume: 260,635 shs
Market Capitalization: $2.10 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $86.00

Get Keros Therapeutics alerts:

Keros Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 47.6% Upside
$86.00 Price Target
Short Interest: Bearish
5.82% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.55
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($5.11) to ($5.42) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.96 out of 5 stars

Medical Sector

371st out of 911 stocks

Pharmaceutical Preparations Industry

165th out of 419 stocks

4.5

Analyst's Opinion

Consensus Rating
Keros Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Keros Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
5.82% of the outstanding shares of Keros Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Keros Therapeutics has a short interest ratio ("days to cover") of 5.1.
Change versus previous month
Short interest in Keros Therapeutics has recently increased by 9.38%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Keros Therapeutics does not currently pay a dividend.
Dividend Growth
Keros Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for KROS.

3.1

News and Social Media Coverage

News Sentiment
Keros Therapeutics has a news sentiment score of 1.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Keros Therapeutics this week, compared to 2 articles on an average week.
Search Interest
Only 1 people have searched for KROS on MarketBeat in the last 30 days. This is a decrease of -90% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Keros Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
28.00% of the stock of Keros Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
71.56% of the stock of Keros Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Keros Therapeutics are expected to decrease in the coming year, from ($5.11) to ($5.42) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Keros Therapeutics is -11.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Keros Therapeutics is -11.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Keros Therapeutics has a P/B Ratio of 5.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Keros Therapeutics Stock (NASDAQ:KROS)

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

KROS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

KROS Stock News Headlines

April 16, 2024 | americanbankingnews.com

Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Update

April 15, 2024 | finance.yahoo.com

Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 37%?

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

April 12, 2024 | americanbankingnews.com

Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Recommendation of "Buy" by Brokerages

March 29, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Keros Therapeutics Amid FDA Approval Landscape and Market Opportunity for KER-012

March 25, 2024 | msn.com

Dyne Therapeutics appoints John Cox CEO

March 19, 2024 | markets.businessinsider.com

Strong Buy Rating for Keros Therapeutics Amid Favorable LR-MDS Treatment Landscape and Regulatory Environment

March 17, 2024 | finance.yahoo.com

KROS Apr 2024 30.000 put

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

March 16, 2024 | finance.yahoo.com

KROS Apr 2024 70.000 put

March 16, 2024 | finance.yahoo.com

KROS Apr 2024 65.000 put

March 16, 2024 | finance.yahoo.com

KROS Apr 2024 75.000 call

March 14, 2024 | finance.yahoo.com

Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes

March 5, 2024 | finance.yahoo.com

Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference

March 1, 2024 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Keros Therapeutics (KROS), Veeva Systems (VEEV) and Capricor Therapeutics (CAPR)

March 1, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Keros Therapeutics Amid Positive Clinical Progress and Strategic Catalysts

March 1, 2024 | finanznachrichten.de

Keros Therapeutics, Inc.: Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

February 29, 2024 | markets.businessinsider.com

Buy Rating Justified by Keros Therapeutics’ Clinical Advancements and Strong Financial Position

February 29, 2024 | markets.businessinsider.com

Optimistic Outlook for Keros Therapeutics’ Advancing Clinical Pipeline Justifies Buy Rating

February 28, 2024 | benzinga.com

Keros Therapeutics Stock (NASDAQ:KROS), Earnings Estimates, EPS, and Revenue

February 28, 2024 | finance.yahoo.com

Keros Therapeutics Inc (KROS) Reports Increased R&D Spending and Net Loss in 2023

February 28, 2024 | globenewswire.com

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

February 26, 2024 | finance.yahoo.com

KROS Mar 2024 70.000 call

February 21, 2024 | benzinga.com

Keros Therapeutics Stock (NASDAQ:KROS) Dividends: History, Yield and Dates

February 21, 2024 | finance.yahoo.com

Does Keros Therapeutics, Inc. (KROS) Have the Potential to Rally 35.66% as Wall Street Analysts Expect?

February 20, 2024 | ca.finance.yahoo.com

KROS Jun 2024 75.000 put

February 18, 2024 | ca.finance.yahoo.com

KROS Sep 2024 30.000 put

See More Headlines

Receive KROS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Keros Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/01/2024
Today: 4/20/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:KROS
CUSIP: N/A
CIK: 1664710
Web: www.kerostx.com
Phone: 617-314-6297
Fax: N/A
Employees: 136
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $86.00
High Stock Price Target: $105.00
Low Stock Price Target: $60.00
Potential Upside/Downside: +47.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($5.20)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-152,990,000.00
Net Margins: N/A
Pretax Margin: -101,319.21%
Return on Equity: -46.74%
Return on Assets: -42.59%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 14.25
Quick Ratio: 14.25

Sales & Book Value

Annual Sales: $150,000.00
Price / Sales: 13,979.43
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $11.09 per share
Price / Book: 5.26

Miscellaneous

Outstanding Shares: 35,980,000
Free Float: 25,908,000
Market Cap: $2.10 billion
Optionable: Optionable
Beta: 1.26

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. Jasbir S. Seehra Ph.D. (Age 68)
President, CEO, Treasurer, & Director
Comp: $985.58k
Mr. Christopher Rovaldi M.Sc. (Age 49)
Chief Operating Officer
Comp: $708.75k
Mr. Keith C. Regnante MBA (Age 54)
Chief Financial Officer
Comp: $603.24k
Ms. Esther Cho J.D.
Senior VP, General Counsel & Secretary
Ms. Robin Wagner
Senior Vice President of Human Resources
Mr. John Oram M.B.A.
Senior Vice President of Program & Portfolio Management

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KROS Stock Analysis - Frequently Asked Questions

Should I buy or sell Keros Therapeutics stock right now?: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Keros Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KROS shares.
View KROS analyst ratings or view top-rated stocks.
What is Keros Therapeutics' stock price target for 2024?: 7 brokers have issued twelve-month price targets for Keros Therapeutics' stock. Their KROS share price targets range from $60.00 to $105.00. On average, they predict the company's share price to reach $86.00 in the next year. This suggests a possible upside of 47.6% from the stock's current price.
View analysts price targets for KROS or view top-rated stocks among Wall Street analysts.
How have KROS shares performed in 2024?: Keros Therapeutics' stock was trading at $39.76 at the start of the year. Since then, KROS shares have increased by 46.6% and is now trading at $58.28.
View the best growth stocks for 2024 here.
Are investors shorting Keros Therapeutics?: Keros Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 2,100,000 shares, an increase of 9.4% from the March 15th total of 1,920,000 shares. Based on an average daily trading volume, of 413,400 shares, the short-interest ratio is currently 5.1 days.
View Keros Therapeutics' Short Interest.
When is Keros Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our KROS earnings forecast.
How were Keros Therapeutics' earnings last quarter?: Keros Therapeutics, Inc. (NASDAQ:KROS) released its earnings results on Friday, March, 1st. The company reported ($1.34) earnings per share for the quarter, topping analysts' consensus estimates of ($1.37) by $0.03. The company had revenue of $0.14 million for the quarter. During the same quarter last year, the business posted ($1.09) earnings per share.

What ETFs hold Keros Therapeutics' stock?: ETFs with the largest weight of Keros Therapeutics (NASDAQ:KROS) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and BNY Mellon Innovators ETF (BKIV).Invesco Dorsey Wright Healthcare Momentum ETF (PTH).
What other stocks do shareholders of Keros Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Keros Therapeutics investors own include AbbVie (ABBV), Brainstorm Cell Therapeutics (BCLI), Cloudera (CLDR), CVS Health (CVS), Inovio Pharmaceuticals (INO), Iovance Biotherapeutics (IOVA), Karyopharm Therapeutics (KPTI), Neurocrine Biosciences (NBIX), Novavax (NVAX) and Pfizer (PFE).
When did Keros Therapeutics IPO?: Keros Therapeutics (KROS) raised $75 million in an IPO on Wednesday, April 8th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, SVB Leerink and Piper Sandler served as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.
Who are Keros Therapeutics' major shareholders?: Keros Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Perpetual Ltd (0.02%). Insiders that own company stock include Christopher Rovaldi, Jennifer Lachey, Julius Knowles, Keith Regnante and Richard K Prins.
View institutional ownership trends.
How do I buy shares of Keros Therapeutics?: Shares of KROS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KROS) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Keros Therapeutics (KROS) Stock Price, News & Analysis

Keros Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Keros Therapeutics Stock (NASDAQ:KROS)

KROS Stock Price History

KROS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

KROS Stock Analysis - Frequently Asked Questions

Overall MarketRank^™